(Q35964727)

11 August 2017

1 reference

title

Atrasentan: targeting the endothelin axis in prostate cancer (English)

1 reference

11 August 2017

1 reference

2

Michael Carducci

1 reference

11 August 2017

Antonio Jimeno

1

1 reference

11 August 2017

language of work or name

English

0 references

publication date

1 December 2004

1 reference

Expert Opinion on Investigational Drugs

11 August 2017

published in

1 reference

11 August 2017

volume

13

1 reference

11 August 2017

issue

12

1 reference

11 August 2017

page(s)

1631-1640

1 reference

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

11 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.12.1631

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.12.1631

Clinical trial design for target-based therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.12.1631

Endothelin receptors as novel targets in tumor therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.12.1631

Role of transactivation of the EGF receptor in signalling by G-protein-coupled receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.12.1631

Growth regulatory properties of endothelins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.12.1631

New therapeutics that antagonize endothelin: promises and frustrations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.12.1631

Role of endothelin in human hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.12.1631

The endothelin axis: emerging role in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.12.1631

Identification of endothelin–1 in the pathophysiology of metastatic adenocarcinoma of the prostate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.12.1631

Role of endothelin-1 in neovascularization of ovarian carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.12.1631

Endothelin-1 as a target for therapeutic intervention in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.12.1631

Endothelin-1 protects ovarian carcinoma cells against paclitaxel-induced apoptosis: requirement for Akt activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.12.1631

Endothelin B receptor blockade inhibits dynamics of cell interactions and communications in melanoma cell progression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.12.1631

Endothelin-1 decreases gap junctional intercellular communication by inducing phosphorylation of connexin 43 in human ovarian carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.12.1631

Endothelin-1 induces an angiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.12.1631

Endothelin-1 induces vascular endothelial growth factor by increasing hypoxia-inducible factor-1alpha in ovarian carcinoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.12.1631

New bone formation in an osteoblastic tumor model is increased by endothelin-1 overexpression and decreased by endothelin A receptor blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.12.1631

Endothelin-1 from prostate cancer cells is enhanced by bone contact which blocks osteoclastic bone resorption

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.12.1631

A causal role for endothelin-1 in the pathogenesis of osteoblastic bone metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.12.1631

Role of endothelin-1 in osteoblastic bone metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.12.1631

Effects of selective endothelin ET(A) receptor antagonists on endothelin-1-induced potentiation of cancer pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.12.1631

Endothelin-B receptor activation triggers an endogenous analgesic cascade at sites of peripheral injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.12.1631

Atrasentan, an endothelin-receptor antagonist for refractory adenocarcinomas: safety and pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.12.1631

Dose-ranging study of the safety and pharmacokinetics of atrasentan in patients with refractory malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.12.1631

10.1517/13543784.13.12.1631

21 January 2018

Identifiers

DOI

1 reference

11 August 2017

1 reference